Clinical Trial Update: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome [Phase 1]

View source ↗

Summary

This update announces a Phase 1 clinical trial of KQ-2003 CAR-T cell therapy for relapsed or refractory POEMS syndrome, which is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poems Syndrome

Drugs mentioned

• KQ-2003 CAR-T Cell Therapy

Snippet

Sponsor: Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Conditions: POEMS Syndrome | Phase 1 | Status: NOT_YET_RECRUITING